ADA2018: Senseonics' Implantable CGM Beats Abbott, Dexcom In Head-To-Head Study – But Is Methodology Flawed?

In a three-way patient study comparing the accuracy of three currently available continuous glucose monitoring (CGM) devices, the newly FDA-approved Eversense by Senseonics performed significantly better than the Abbott Freestyle Libre Pro and Dexcom G5. The study findings were presented during this year's annual American Diabetes Association meeting in Orlando, Florida. This article also discusses other highlights presented by the three companies at the ADA conference.

Diabetes equipment set. Glucose meter. Glucose blood test. Diabetes equipment, Insulin pen. Insulin Pumps. Bloodless glucometer. Continuous Glucose Monitoring. Portable Glucometer on white background

In a head-to-head study comparing the accuracy of three available continuous glucose monitoring (CGM) devices – Dexcom Inc.'s G5 (not the newly licensed G6), Abbott Diabetes Care Inc.'s Freestyle Libre Pro (not the patient version) and Senseonics Holdings Inc.' Eversense, an implantable device – in a real world outpatient setting, the point accuracy of the Eversense CGM system was significantly better than the other two systems, Rabab Jafri of Massachusetts General Hospital, Boston wrote in the July issue of the American Diabetes Association's medical journal Diabetes.

Findings of the study involving 23 adults with type 1 diabetes, who wore all three devices concomitantly at home for...

Medtech Insight Podcast

Keep up with the top medtech business and regulatory news.

Medtech Insight brings you interviews and analysis, on the go.

More from Diabetic Care

J&J MedTech Keeps Up Cardiovascular Momentum With Shockwave E8 Launch In US

Tim Schmid, executive VP and worldwide chairman of J&J MedTech, expects Shockwave, acquired in April, and Abiomed, purchased in late 2022, to be “long-term gems” for the company. Cardiovascular is among higher-growth segments where J&J has concentrated investments in recent years, along with robotic surgical systems.

Pilot To Program: FDA Issues Accreditation Scheme For Conformity Assessment Draft Guidances

 

The US FDA has published a trio of draft guidance documents for its Assessment Scheme for Conformity Program, which began as a pilot in September 2020 to capitalize on the role of standards in the regulation of medical devices.

News We’re Watching: Trial Lab Warning Letters, Novartis Adds US Plants, Abbott Launches OTC Lingo Glucose Monitor

 

This week, two device testing labs in China landed FDA warning letters; refunds for 1Health.io clients; FDA AR/VR product list expands. 

News We’re Watching: $1B Judgement Against J&J Recalls For Abbott, Baxter, More; Karl Storz Announces Fujifilm Partnership

 

This week, a Delaware court awarded Auris Health shareholders $1bn in a lawsuit against Johnson & Johnson; Abbott recalled some FreeStyle Libre 3 sensors; and McKesson purchased a controlling interest in a Florida cancer care chain.

More from Device Area

Owkin Teams With AstraZeneca To Develop AI-Based Breast Cancer Prescreening Tool

 

Biopharmaceutical giant AstraZeneca has partnered with start-up “unicorn” Owkin to develop an AI-powered tool to prescreen for gBRCA mutations on the basis of morphological features in digitized pathology slides. Built on extensive, high-quality data sourced from the France-based PortrAIt consortium, the AI will help to prioritize patients for further testing, streamlining the diagnostic process, Owkin says.

Route 92 To Drive FreeClimb Neurointervention Sales With Extended Series F Funding

 

An additional $50m brings the neurovascular intervention specialist’s total Series F funding to $82m. Route 92 says it will use the capital to build its sales and support teams and pursue regulatory authorizations around the globe for its FreeClimb portfolio while advancing its SUMMIT MAX clinical trial for the investigational Monopoint Reperfusion System.

TRiCares Initiates EU Pivotal Study For Topaz Tricuspid Valve Replacement

 

TRiCares announced first implantation of the Topaz transfemoral tricuspid heart valve replacement system as part of the company’s EU pivotal study. If all goes to plan, the device will compete with Edwards’ Evoque system. The announcement follows the company’s $50m series D funding raise in July.